Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;395:2008–20.

Article  CAS  PubMed  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

Article  PubMed  Google Scholar 

Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936–45.

Article  PubMed  Google Scholar 

Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–86.

Article  PubMed  Google Scholar 

Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44–56.

Article  CAS  PubMed  Google Scholar 

Gubin MM, Artyomov MN, Mardis ER, et al. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125:3413–21.

Article  PubMed  PubMed Central  Google Scholar 

Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med. 2017;377:1409–12.

Article  PubMed  Google Scholar 

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10.

Article  CAS  PubMed  Google Scholar 

Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392–400.

Article  PubMed  Google Scholar 

Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3:1197–203.

Article  PubMed  Google Scholar 

Shulman K, Barnett-Griness O, Friedman V, et al. Outcomes of chemotherapy for microsatellite instable-high metastatic colorectal cancers. JCO Precis Oncol. 2018. https://doi.org/10.1200/PO.17.00253.

Article  PubMed  PubMed Central  Google Scholar 

Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mukai Y, Ueno H. Establishment and implementation of cancer genomic medicine in Japan. Cancer Sci. 2021;112:970–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kohno T, Kato M, Kohsaka S, et al. C-CAT: The national datacenter for cancer genomic medicine in Japan. Cancer Discov. 2022;12:2509–15.

Article  PubMed  PubMed Central  Google Scholar 

Kundra R, Zhang H, Sheridan R, et al. OncoTree: a cancer classification system for precision oncology. JCO Clin Cancer Inform. 2021;5:221–30.

Article  PubMed  Google Scholar 

Food and Drug Administration. Summary of Safety and Effectiveness Data (FoundationOne CDx) https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S014B.pdf. Accessed 6 Mar 2023.

Food and Drug Administration. Summary of Safety and Effectiveness Data (FoundationOne Liquid CDx) https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190032B.pdf. Accessed 6 Mar 2023.

Milbury CA, Creeden J, Yip WK, et al. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE. 2022;17: e0264138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of foundationone liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE. 2020;15: e0237802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sunami K, Ichikawa H, Kubo T, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. 2019;110:1480–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sysmex Corporation. Sysmex receives approval for a partial change to the oncoguideTM NCC oncopanel system for use in cancer genome profiling. https://www.sysmex.co.jp/en/news/2021/pdf/210215.pdf. Accessed 7 Mar 2023.

Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gröbner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555:321–7.

Article  PubMed  Google Scholar 

Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171:1042-56.e10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pishvaian MJ, Blais EM, Brody JR, et al. Outcomes in Patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumor program. JCO Precis Oncol. 2019;3:1–10.

PubMed  Google Scholar 

Kondo T, Kanai M, Kou T, et al. Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget. 2018;9:19817–25.

Article  PubMed  PubMed Central  Google Scholar 

Singhi AD, George B, Greenbowe JR, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology. 2019;156:2242-53.e4.

Article  CAS  PubMed  Google Scholar 

Chakrabarti S, Bucheit L, Starr JS, et al. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022;10:e004485.

Article  PubMed  PubMed Central  Google Scholar 

Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res. 2018;24:1326–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70:148–56.

Article  CAS  PubMed  Google Scholar 

Umemoto K, Yamamoto H, Oikawa R, et al. The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. J Natl Cancer Inst. 2022;114:1279–86.

Article  PubMed  PubMed Central  Google Scholar 

Philip PA, Azar I, Xiu J, et al. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res. 2022;28:2704–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23:3711–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8:1751.

Article  PubMed  PubMed Central  Google Scholar 

Yap TA, Bardia A, Dvorkin M, et al. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial. JAMA Oncol. 2023;9:40–50.

Article  PubMed  Google Scholar 

Schram AM, Colombo N, Arrowsmith E, et al. Avelumab plus talazoparib in patients with BRCA1/2- or ATM-Altered advanced solid tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b tumor-agnostic trial. JAMA Oncol. 2023;9:29–39.

Article  PubMed  Google Scholar 

Karamitopoulou E, Andreou A, Wenning AS, et al. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Eur J Cancer. 2022;169:64–73.

Article  CAS  PubMed  Google Scholar 

Liao C, Huang W, Lin M, et al. Correlation of KMT2 family mutations with molecular characteristics and prognosis in colorectal cancer. Int J Biol Markers. 2022;37:149–57.

Article  CAS  PubMed  Google Scholar 

Tokunaga R, Xiu J, Goldberg RM, et al. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. Eur J Cancer. 2020;140:119–29.

Article  CAS  PubMed  Pu